• Smile Brands Scoops Up Dentistry of Sarasota

    On December 2, Smile Brands, one of the largest providers of dental support services in the United States, announced its new partnership with Dentistry of Sarasota. Financial terms of the deal were not disclosed. Smile Brands provides business support services to general and multi-specialty dental groups since its founding in 1998. The company... Read More »
  • Ingenovis Health to Acquire HealthCare Support

    Ingenovis Health, Inc., one of the fastest-growing providers of healthcare staffing, announced on November 29 that it has agreed to acquire HealthCare Support, a national healthcare staffing platform providing a full range of customized hiring solutions across the country. Financial terms of the transaction, which is expected to close in the... Read More »
  • Edifecs to Acquire Health Fidelity

    On November 22, Edifecs, Inc. announced that it has signed a definitive agreement to acquire Health Fidelity, a leading provider of risk adjustment solutions for the value-based care era. The acquisition is expected to close in mid-December of this year, pending regulatory approval. Founded in 1996, Edifecs is a premier technology company in the... Read More »
  • Israeli Startup TailorMed Acquires Vivor

    On November 29, TailorMed, a leading financial navigation platform that helps healthcare organizations and patients remove financial barriers to care, announced that it has acquired Vivor, a financial assistance technology platform for healthcare providers and life sciences. The financial terms of the transaction were not disclosed. TailorMed is... Read More »
  • HomeCentris Healthcare Acquires Grace Home Healthcare

    On November 26, HomeCentris Healthcare, LLC announced that it had acquired Grace Home Healthcare, LLC. The deal was closed in October for an undisclosed amount. Headquartered in Owings Mills, Maryland, HomeCentris Healthcare, LLC is an independent home and community-based care organization. It was founded in 2000 and provides its services to... Read More »
Takeda Adds Maverick Therapeutics

Takeda Adds Maverick Therapeutics

The pharmaceutical giant Takeda Pharmaceutical Co. Ltd. (NYSE: TAK) is back with a new acquisition. The company has announced the acquisition of Maverick Therapeutics, Inc for a pre-negotiated upfront payment as well as potential development and regulatory milestones totaling up to $525 million. This acquisition follows a multi-year collaboration between Takeda and Maverick, signed in 2017.  Maverick Therapeutics is a privately held biopharmaceutical company pioneering conditionally active bispecific T-cell targeted immunotherapies. Its lead candidates are MVC-280 (now TAK-280) and MVC-101 (now TAK-186). TAK-186 is currently in a Phase 1/2 study for the treatment of EFGR-expressing solid... Read More »
Amgen Acquires Five Prime Therapeutics

Amgen Acquires Five Prime Therapeutics

The biotech giant Amgen, Inc. (NASDAQ: AMGN) has announced a new deal for Five Prime Therapeutics (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies. The company collaborates with leading global pharmaceutical companies and has therapies in pre-clinical and clinical development.  Amgen will acquire Five Prime Therapeutics for $38.00 per share in cash, representing an equity value of approximately $1.9 billion. The dollar-per-share amount is a 78% premium to Five Prime’s closing price on March 3, 2021. The transaction comes out to an estimated 232x Five Prime Therapeutics’ annualized revenues. However, the company... Read More »
Merck Boosts Autoimmune Portfolio With New Deal

Merck Boosts Autoimmune Portfolio With New Deal

The pharmaceutical giant Merck & Co., Inc. (NYSE: MRK) is back with a new deal, acquiring Pandion Therapeutics, Inc. (NASDAQ: PAND) for $1.85 billion, or $60 per share in cash, a 134% premium to the prior day’s closing price. Pandion Therapeutics is developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases. Pandion’s TALON (Therapeutic Autoimmune reguLatOry proteiN) drug design and discovery platform enable the company to create a pipeline of product candidates using immunomodulatory effector modules.  In 2020, the company generated approximately $10.5 million in revenue, but reported a loss in EBITDA of approximately $43.2 million. ... Read More »
MindMed Acquires HealthMode

MindMed Acquires HealthMode

MindMed (OTCQB: MMEDF), a New York City-based biotechnology company, is expanding its platform with a new deal. Last week, the company announced it is acquiring HealthMode, a digital medicine and therapeutics startup that uses artificial intelligence-enabled digital measurement to increase the precision and speed of clinical research and patient monitoring. MindMed will issue 8,250,836 subordinate voting shares at the Feb. 17, 2021 closing price of CAD 5.13, plus approx. CAD 300,000 in cash. Based on the conversion rate from February 18, 2021, the price comes out to approximately U.S. $33.67 million. The acquisition of Healthmode is expected to close by the end of February 2021. MindMed is... Read More »
Humacyte Goes Public Via SPAC

Humacyte Goes Public Via SPAC

Humacyte, Inc. announced last week it is merging with Alpha Healthcare Acquisition Corp. (NASDAQ: AHAC), a special purpose acquisition company (SPAC). Shareholders of Humacyte will get an aggregate of 80 million shares of AHAC’s common stock, or roughly $800 million. Humacyte is a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue on a commercial scale. The company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular... Read More »
Horizon Therapeutics Acquires Viela Bio

Horizon Therapeutics Acquires Viela Bio

Horizon Therapeutics plc (NASDAQ: HZNP) has been a major player in the healthcare M&A market for the last few years. According to search results in our Healthcare Deal Database, the company last reported a deal in April 2020, acquiring Curzion Pharmaceuticals, Inc., a San Diego-based biotechnology firm developing treatments for rare fibrotic diseases, for a modest $45 million. However, Horizon Therapeutics is back with a new deal, buying Viela Bio, Inc. in a $3.05 billion deal.  Viela Bio is a biotechnology company dedicated to the discovery, development and commercialization of novel treatments for autoimmune and severe inflammatory diseases. The company has a substantial pipeline... Read More »